Experimental drug brincidofovir targets Hard-to-Treat lymphomas

NCT ID NCT06761677

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called brincidofovir in people with lymphoma (a type of blood cancer) that has returned or not improved after standard treatments. The trial has two parts: first, finding a safe dose in up to 18 people with various lymphomas, then testing that dose in 25 people with a rare subtype called ENKL. The goal is to see if the drug can shrink tumors and to understand its side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ADULT T-CELL LEUKEMIA LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cancer Institute Hospital Of JFCR

    Kōtoku, Japan

  • Kyoto University Hospital

    Kyoto, Japan

  • Mie University Hospital

    Tsu, Japan

  • National Cancer Center Hospital

    Chūōku, Japan

  • National Cancer Centre Singapore

    Singapore, Singapore

  • Okayama University Hospital

    Okayama, Japan

  • Queen Mary Hospital

    Hong Kong, China

  • Tokyo Metropolitan Komagome Hospital

    Bunkyō City, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.